Study #2021-1169
REAL-MIND: Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant
MD Anderson Study Status
Enrolling
Treatment Agent
Tafasitamab
Description
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Diffuse Large B-cell Lymphoma
Study phase:
Physician name:
Dai Chihara
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-855-760-2503
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.